CAS: 57-92-1; Streptomicin

该化合物是一种主要用于治疗某些细菌,特别是与肺结核有关的细菌所造成感染的寄生虫体抗生素,主要用于治疗某些细菌,尤其是与肺结核有关的细菌引起的感染,由细菌* 链球菌毛片* 产生,结构复杂,包括氨基糖和乙氧成分.通过抑制细菌蛋白合成,特别是约束于干扰翻译过程的30S 肋骨菌子细胞,施球菌素功能.这种抗生素对各种抗长效和某些抗长效细菌有效.由于肠道吸收不良,通常通过注射进行.常见副作用可能包括食毒,...

英文名称Streptomicin
中文名称链霉素
IUPAC名称2-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine
其它别名N,N'''-[(1S,2S,3S,4R,5S,6R)-4-({5-Deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-D-mannopyranosyl]-3-C-formyl-beta-D-ribofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine
CAS编号57-92-1
MFCD编号:MFCD00072108
EINECS号:200-355-3
FDA UNII编号:Y45QSO73OB
分子式:C21H39N7O12
分子量:581.58
产品CID: 1554212
产品分类原料药 → 抗生素类药物 → 氨基糖苷类药

相似结构搜索
InChIKey: UCSJYZPVAKXKNQ-HZYVHMACSA-N
InChI=1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35…
计算化学: 氢键受体数15.0氢键供体数12.0可旋转键数9.0

物理性质

熔点194 °C
沸点639.94°C (粗估)
闪点527.281 °C
密度1.4142 (粗估)
pKa:pKa 7.84(H2O t = 25 I = 0.1) (Uncertain);11.54(H2O t = 25 I = 0.1) (Uncertain);>12(H2O t = 25 I = 0.1) (Uncertain)
PSA:331.43
LogP:-4.969
折射率1.6800 (估算)
蒸汽压5.82X10-28 mm Hg at 25 °C (est)
溶解性Miscible with water at 25 °C (1.0X10+6 mg/L) (est)
外观形态白色至类白色固体
储存条件2-8°C
产品应用链霉素(57-92-1)的用途其属抗生素类杀菌剂,为放线菌所产生的代谢产物,杀菌谱广,特别是对细菌性病害效果较好,具有内吸作用,能渗透到植物体内,并传导到其他部位.用于防治多种作物细菌性病害,对一些真菌病害也有一定的防治作用.农用链霉素是灰链丝菌分泌的抗菌素,有内吸治疗作用,对植物细菌性病害有较好的防治效果.可有效地防治植物的细菌病害,例如苹果,梨火疫病,烟草野火病,蓝霉病,白菜软腐病,蕃茄细菌性斑腐病,晚疫病,马铃薯种薯腐烂病,黑胫病,黄瓜角斑病,霜霉病,菜豆霜霉病,细菌性疫病,芹菜细菌疫病,芝麻细菌性叶斑病.主要用于防治水稻白叶枯病,细菌性条斑病,柑橘溃疡病,黄瓜细菌性角斑病等.可做喷雾,灌根,浸种用.

MSDS等安全信息

GHS象形图
GHS符号GHS08;
注释: Health hazard
危险类别致癌性类别2
生殖毒性类别2
急性毒性类别4(经口)
警示词Warning(警告)
危险描述H351 |怀疑致癌.
H361 |怀疑对生育能力或胎儿造成损害.
H361fd |怀疑会影响生育能力. 怀疑对胎儿造成损害.
H302 |吞咽有害.
防范说明P261-P305+P351+P338
安全声明IDENTIFICATION AND USE: Streptomycin is aminoglycoside anti-bacterial agent. HUMAN EXPOSURE AND TOXICITY: Streptomycin has been replaced by gentamicin for most indications because the toxicity of gentamicin is primarily renal and reversible, whereas that of streptomycin is vestibular and irreversible. The administration of streptomycin may produce dysfunction of the optic nerve, including scotomas, presenting as enlargement of the blind spot. Among the less common toxic reactions to streptomycin is peripheral neuritis. This may be due either to accidental injection of a nerve during the course of parenteral therapy or to toxicity involving nerves remote from the site of antibiotic administration. Serious sensitivity reactions, such as anaphylaxis and dermatologic reactions including exfoliative dermatitis, toxic epidermal necrolysis, erythema multiforme, angioedema, and Stevens-Johnson syndrome, have been reported rarely in patients receiving aminoglycosides; fatalities have occurred rarely. Cross-sensitivity occurs among the aminoglycosides. ANIMAL STUDIES: Clinical signs of toxicity in mice included restlessness, respiratory depression, loss of balance, unconsciousness, motor paralysis and coma following all routes of administration. Coma was more often associated with subcutaneous dosing. After oral dosing, restlessness and excessive thirst were observed, possibly due to an osmotic effect. Intravenous and subcutaneous administration of 30 to 70 mg/kg bw streptomycin to monkeys caused marked respiratory depression which sometimes necessitated artificial respiration. Intravenous injection of streptomycin at doses of 100 to 200 mg/lb bw (220-440 mg/kg bw) in dogs caused an irreversible depression of blood pressure. Respiration was stimulated by low but paralyzed by high (165 mg/kg bw) intravenous doses. A daily dose of streptomycin of 25-75 mg/lb bw/day (55-165 mg/kg bw/day) to cats caused progressive changes in posture and gait over about 20 days, including ataxia (of the hind legs first then fore-legs), and a progressive rotational nystagmus. Withdrawal of the drug resulted in a slow but complete recovery of vestibular function. Streptomycin was administered subcutaneously to 14 pregnant mice at 400 ug/kg bw/day on days 9, 10, and 11 of pregnancy. Twenty-eight mice used as controls were injected with water. The number of implants was reduced in treated mice (179 vs 351 in controls). Early deaths were higher in controls (3.9% in the streptomycin group vs 5.1% in controls). | Monitoring for streptomycin toxicity is especially important in the young and patients with renal impairment, as streptomycin occurs via glomerular filtration. Renal impairment can prolong the drug's half-life by 50 to 100 hours. Ototoxicity and vestibular impairment are often thought to be the hallmark of streptomycin toxicity. In extreme cases, deafness may occur due to ototoxicity; thus, caution must be exercised when combining streptomycin with other potentially ototoxic drugs. Vestibular impairment usually manifests during the course of treatment and is typically permanent. Streptomycin is also a potentially nephrotoxic agent. This will manifest as mild proteinuria, excess cellular excretion, and mild elevations in blood urea. Unlike ototoxic effects, nephrotoxicity is usually only transient. There are also reports of neuromuscular blockade with streptomycin use in association with installation into body cavities, use during anesthesia involving the use of neuromuscular blocking agents, and overdose in children. Neurotoxic effects can lead to optic nerve dysfunction, peripheral neuritis, and encephalopathy. Intrathecal use, while rarely used, has been associated with arachnoiditis. In the event of drug toxicity, dialysis can lower serum streptomycin concentration.
危险类别码Immunological contact urticaria documented in pharmaceutical and healthcare workers; [Kanerva, p. 219]
WGK Germany-

欧盟法规

ECHA物质ECHA物质C&L通报REACH预注册

合成工艺路线路线简述

磷酸肌酸,硫酸链霉素置于5'-腺嘌呤核苷酸体系中,化学反应生成链霉素
参考文献:Adenylate Kinase And Process For The Production Thereof
标题:Adenylate Kinase And Process For The Production Thereof
摘要:本文描述了一种耐热腺苷酸激酶,其在约50oc的缓冲溶液中孵育约15分钟后的活性至少为孵育前的原始活性的80%以上.这种腺苷酸激酶可以通过培养属于芽孢杆菌属的细菌并从所得的培养液中收集腺苷酸激酶来获得.这种耐热酶对热非常稳定,因此,在分离后,与传统的腺苷酸激酶相比,它可以长时间储存.

海关参考信息

2905122000-异丙醇
2905143000-叔丁醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:EP-2097079-B1
优先权日:2006-11-30
标题:Modulation of prostaglandin/cyclooxygenase metabolic pathways
发明人：WUELFERT ERNST
权利人:HUNTER FLEMING LTD
摘要:A variety of diseases and disorders associated with the metabolic pathways involved in the activities of cyclooxygenase and the synthesis of prostaglandins, for example type 2 diabetes mellitus and its sequelae, ischemic vascular diseases, pain associated with inflammation, inflammatory skin conditions, spinal cord injury, peripheral neuropathy, multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis, as well as various types of cancer may be treated or prevented by the use of an agent which selectively enhances production of 15-deoxy-prostaglandin J2. The compounds are 7-hydroxy-steroids or condensed indoles.

专利号:US-10457964-B2
优先权日:2014-04-27
标题:Method for increasing the biomass synthesis capacity of a photosynthetic microorganism
发明人：DAS GAUTAM; DASGUPTA SANTANU; PRASAD VENKATESH; VIJAYAKUMAR VINODHKUMAR; DEORE PRANALI; KALIYAMOORTHY KANNADASAN; KUMARI SUJATA
权利人:RELIANCE INDUSTRIES LTD
摘要:The present disclosure relates to a method for increasing biomass synthesis capacity of microorganisms. The method in accordance with the present disclosure comprises overexpressing the genes involved in protein synthesis to increase the levels of protein synthesis and thereby, increase the biomass synthesis capacity of the microorganisms. The present disclosure also provides a modified microorganism having increased biomass synthesis capacity.

专利号:US-2003138490-A1
优先权日:2001-09-08
标题 :Synthesis and uses of polymer gel nanoparticle networks
发明人：HU ZHIBING; LU XIHUA; GAO JUN; PONDER BILL C; JOHN JOHN ST; MORO DANIEL G
摘要:Disclosed is a new class of nanostructured polymeric materials comprising polymer gel nanoparticles that are covalently bonded through functional groups on the surfaces of neighboring particles. These nanoparticles may be prepared as suspensions in an aqueous or, non-aqueous environment. These gels have two unique and different structural networks; the primary network comprises crosslinked polymer chains in each individual particle, while the secondary network is a system of crosslinked nanoparticles. Particular polymer gel nanoparticle network compositions disclosed herein may function as carriers for controlled delivery of pharmaceuticals or other chemical agents, gel sensors and other commercial applications.

专利号:US-2008051323-A1
优先权日:2004-08-21
标题 :Chloroquine drug compositions and methods for their synthesis
发明人：KOSAK KENNETH M
权利人:KOSAK KENNETH M
摘要:This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. n The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and active agents to their site of action.

专利号:US-2007232495-A1
优先权日:2006-03-24
标题:Compositions and methods to add value to plant products, increasing the commercial quality, resistance to external factors and polyphenol content thereof
发明人：NAPPA ALVARO O; LORENZINI FELIPE C; SANHUEZA ANDRES L
权利人:NAPPA ALVARO O; LORENZINI FELIPE C; SANHUEZA ANDRES L
摘要:The invention is related to compositions and methods that naturally protect plant tissues against ultraviolet radiation and temperature, thus giving protection against sunburn to plants, plant parts, fruits and/or flowers during their development. The invention is also related to compositions and methods to naturally improve the color of plants, plant parts, fruits and/or flowers by inducing the natural synthesis of flavonoids and anthocyanins present in plants. Likewise, the present invention is directed to improving the nutritional value of plants, plant parts, fruits and/or flowers by increasing the normal levels of polyphenolic compounds, especially flavonoids, present therein. Additionally, the present invention is related to compositions and methods that give more resistance to plants, plant parts, fruits and/or flowers against pathogens as bacteria and fungi. Finally, the present invention is related to plants, plant parts, fruits, flowers and/or propagating material treated with the compositions described in the present document.

专利号:US-2007060499-A1
优先权日:2005-09-15
标题 :Chloroquine combination drugs and methods for their synthesis
发明人：KOSAK KENNETH M
权利人:KOSAK KENNETH M
摘要:This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and active agents to their site of action.